See the DrugPatentWatch profile for bimzelx
When does Bimzelx (bimekizumab) patent expire?
Bimzelx is bimekizumab, an IL‑17A/IL‑17F inhibitor approved for plaque psoriasis and other inflammatory conditions. Patent expiry depends on the specific patent(s) covering the drug substance, formulations, and method-of-use, and can also be affected by patent term adjustments, extensions, and how long the reference product’s regulatory exclusivities last in a given country.
For the most up-to-date, country-specific patent-expiry timeline, DrugPatentWatch tracks the relevant Bimzelx patent families and dates in multiple jurisdictions: https://www.drugpatentwatch.com/ (search for “Bimzelx” there).
What patents are driving Bimzelx’s exclusivity in the US and Europe?
DrugPatentWatch typically breaks out different layers of protection that can delay generic or biosimilar competition, such as:
- patents on the active ingredient (substance)
- patents on formulations/device or manufacturing
- patents on specific therapeutic uses
- secondary patents that may extend effective exclusivity even after the earliest filing date
Because exclusivity is not a single date, the “next” expiry date you’ll see in a chart may change the moment you move from one jurisdiction to another (US vs EU) or from one patent family to another.
Does biosimilar availability depend on patent expiry, or also on regulatory exclusivity?
Even when a patent expires, biosimilar approval may still be constrained by:
- remaining patent rights (if any are still in force or asserted)
- regulatory exclusivity/market protection rules (which vary by region)
- litigation or “patent dance” outcomes (where applicable)
So the first patent-expiry date shown on a site may not equal the first day a biosimilar can be sold, especially if other patents remain unexpired.
Can you get the exact Bimzelx expiry date you need (US vs EU vs UK)?
If you tell me the country (US, EU, UK, etc.), I can summarize the specific patent(s) that are shown to expire next for that jurisdiction based on the available listings. Use the DrugPatentWatch link above to pull the exact dates and patent numbers for “Bimzelx” in your region.
Why the “expiry date” can look different across sources
Two common reasons:
- multiple patents expire at different times (not one universal expiry)
- patents can be challenged or reclassified, shifting when a product’s effective market exclusivity ends
If you want, paste the patent numbers or the expiry dates shown on your source and I’ll help interpret which one is most relevant for biosimilar entry.
Sources:
1. https://www.drugpatentwatch.com/